Article
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
European journal of haematology - 1 Dec 2023
Kockerols Camille, Valk Peter J M, Blijlevens Nicole M A, Cornelissen Jan J, Dinmohamed Avinash G, Geelen Inge, Hoogendoorn Mels, Janssen Jeroen J W M, Daenen Laura G M, Reijden Bert A van der, Westerweel Peter E
Abstract excerpt
OBJECTIVES: Acquired missense mutations in the BCR::ABL1 kinase domain (KD) may cause tyrosine kinase inhibitor (TKI) treatment failure. Based on mutation-specific in vitro derived IC50-values, alternative TKI may be selected. We assessed clinical practice of BCR::ABL1 KD mutation testing, clinical response in relation to IC50-values, and clinical outcome of tested patients. METHODS: Patients from six Dutch CML...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.